Jill Kalman, MD
Cardiovascular Disease · New York, NYNPI 1528034352
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $165,834 of the $189,326 with a category attached, or 87.6%. Longeviti Neuro Solutions Inc accounts for 99.9% of it on its own, with 2 other manufacturers making up the rest. 2025 is the largest year on record at $162,004, more than ten times the $220 reported in 2021. Among cardiovascular disease clinicians in NY with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 11 payments — averaging $17,211 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Longeviti Neuro Solutions Inc$189K
- Insightec,inc$256
- Amgen$16
What the payments were for
- Consulting fees$23,00012%
- Speaking & faculty fees$165,83488%
- Food & beverage$4920%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Longeviti Neuro Solutions Inc | 7 | $189,055 |
| Insightec,inc | 3 | $256 |
| Amgen | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- CLEARFIT$189,055
- INVISISHUNT$220
- Exablate$132
How this compares
$189,326 in reported general payments places this provider in the 95th percentile of 2,302 cardiovascular disease providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EntrestoSacubitril/Valsartan | 31 | $36,854 |
| Valsartan | 15 | $568 |
| Metoprolol Succinate | 20 | $328 |
| Amlodipine Besylate | 11 | $146 |
| Atorvastatin Calcium | 11 | $137 |
| Rosuvastatin Calcium | 12 | $75 |
Paid to pharmacies, not to this prescriber.
Other cardiovascular disease in New York
- Roger HajjarNew York$5.2M
- Gregg StoneNew York$2M
- Philippe GenereuxNew York$1.3M
- Adam RosenbluthNew York$1.1M
- Megha PrasadNew York$813K
- Eyal HerzogNew York$645K
- Nisha JhalaniNew York$443K
- Roxana MehranNew York$432K
- Howard WeintraubNew York$328K
- Anuradha Lala-TrindadeNew York$324K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.